As part of the transaction, Intellia will pay Rewrite shareholders $45 million in an upfront payment and an additional $155 million in prespecified research and regulatory approval milestones through a mix of Intellia common stock and cash. Additional financial details were not disclosed.

Intellia Therapeutics, a clinical-stage genome editing company, is developing novel therapeutics leveraging CRISPR-based technologies. Rewrite Therapeutics' proprietary and versatile DNA writing platform enables a range of novel genome editing strategies.

FDA grants orphan drug designation to Intellia's NTLA-2001
The U.S. Food and Drug Administration has granted an orphan drug designation to Intellia Therapeutics' NTLA-2001 therapy for the treatment of transthyretin...

Next-generation gene therapy points to base editing
Base editing has emerged as a new player in the gene therapy arena, with rapid advances in technology and evidence of proof of concept in rare genetic...

Intellia reports net loss in Q2
Intellia Therapeutics reported a net loss for the second quarter of 2021, which ended June 30.

Intellia, Regeneron highlight clinical results for CRISPR-Cas9 gene therapy
Intellia Therapeutics and Regeneron Pharmaceuticals have announced positive interim data from an ongoing phase I study of their in vivo candidate, NTLA-2001,...